1980
DOI: 10.1016/0161-5890(80)90119-4
|View full text |Cite
|
Sign up to set email alerts
|

The physiological breakdown of the third component of human complement

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

7
94
2

Year Published

1981
1981
2019
2019

Publication Types

Select...
6
2

Relationship

0
8

Authors

Journals

citations
Cited by 185 publications
(103 citation statements)
references
References 31 publications
7
94
2
Order By: Relevance
“…The formation of C3bi described here is in agreement with the findings in [15]. The failure to observe the double cleavage of the a'-chain of C3b in [6,7, 10-14] may be explained by the transient appearance of the 46 000 M r fragment, especially around neutral pH.…”
Section: Discussionsupporting
confidence: 81%
See 1 more Smart Citation
“…The formation of C3bi described here is in agreement with the findings in [15]. The failure to observe the double cleavage of the a'-chain of C3b in [6,7, 10-14] may be explained by the transient appearance of the 46 000 M r fragment, especially around neutral pH.…”
Section: Discussionsupporting
confidence: 81%
“…The ~'-chain of C4b is cleaved in two places by C3b/C4b INA [8,9]. However, there is controversy as to whether the a'-chain of C3b is cleaved at a single peptide bond [6,7,[10][11][12][13][14] or in two places [15] by C3b/C4b INA. The product of C3b degradation by/31H and C3b/C4b INA is called C3bi.…”
Section: Introductionmentioning
confidence: 99%
“…The citrullination was found to be on position 1320, the C-terminal aa of the C3f fragment. C3f is a peptide that is released in vivo when C3b is converted to C3ib by the serine protease Factor I during complement activation [28,29]. Therefore, it seems likely that this is an example of the citrullinations that might be missed when implementing the no C-terminal citrullination limitation.…”
Section: Citationmentioning
confidence: 99%
“…Serum complement is of major importance in the humoral immune response to pyogenic infections, and C3 is currently viewed as the target molecule of both the classical and the alternative pathways of complement activation [1][2][3]. Its acReceived for publication March 10, 1981, and in revised form June 22, 1981.…”
mentioning
confidence: 99%
“…Its ac-tivation leads to the production of the biologically active fragment C3b, and the coating of microorganisms with C3b promotes their recognition by PMNLs. Activation proceeds through the cleavage of native C3 by either the classical (C42) or the alternative (C3b, Bb) pathway convertase of C3 or both [2,3]. Recently it has been shown in vitro [4][5][6][7][8] that C3, as well as C5, can be split by complement-unrelated enzymes, such as purified neutral proteases from PMNLs.…”
mentioning
confidence: 99%